Your browser is no longer supported. Please, upgrade your browser.
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.39 Insider Own0.10% Shs Outstand58.24M Perf Week-0.94%
Market Cap4.80B Forward P/E- EPS next Y-7.55 Insider Trans-71.07% Shs Float57.42M Perf Month7.59%
Income-404.70M PEG- EPS next Q-2.11 Inst Own91.70% Short Float5.95% Perf Quarter22.88%
Sales0.30M P/S15986.97 EPS this Y-196.10% Inst Trans3.09% Short Ratio6.70 Perf Half Y17.88%
Book/sh18.55 P/B4.33 EPS next Y8.60% ROA-33.10% Target Price94.73 Perf Year82.20%
Cash/sh18.50 P/C4.34 EPS next 5Y- ROE-36.10% 52W Range32.95 - 90.19 Perf YTD4.58%
Dividend- P/FCF- EPS past 5Y-9.90% ROI-36.70% 52W High-10.91% Beta0.73
Dividend %- Quick Ratio19.60 Sales past 5Y-52.60% Gross Margin- 52W Low143.85% ATR3.20
Employees363 Current Ratio19.60 Sales Q/Q-98.80% Oper. Margin- RSI (14)52.39 Volatility5.14% 3.93%
OptionableYes Debt/Eq0.04 EPS Q/Q-19.00% Profit Margin- Rel Volume1.04 Prev Close79.49
ShortableYes LT Debt/Eq0.04 EarningsFeb 23 AMC Payout- Avg Volume510.55K Price80.35
Recom1.70 SMA200.21% SMA503.22% SMA20014.05% Volume528,992 Change1.08%
Nov-10-20Reiterated Guggenheim Buy $115 → $105
Sep-14-20Resumed JP Morgan Overweight $71
Jun-29-20Initiated H.C. Wainwright Buy $90
May-18-20Initiated Jefferies Buy $62
Mar-31-20Initiated Guggenheim Buy $95
Mar-26-20Upgrade BofA/Merrill Neutral → Buy $47 → $56
Jan-31-20Upgrade JP Morgan Neutral → Overweight $58
Nov-13-19Initiated BofA/Merrill Neutral $51
Dec-13-18Initiated Berenberg Buy $55
May-31-18Initiated RBC Capital Mkts Outperform $65
Mar-21-18Upgrade Needham Hold → Buy $60
Mar-20-18Reiterated JMP Securities Mkt Outperform $63 → $79
Jan-18-18Resumed Credit Suisse Outperform $44
Jan-18-18Initiated Credit Suisse Outperform $44
Jan-03-18Upgrade Wells Fargo Market Perform → Outperform
Jul-11-17Reiterated Citigroup Buy $23 → $37
Jul-07-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jun-27-17Initiated Citigroup Buy $23
May-19-17Initiated Leerink Partners Outperform $5
Sep-15-16Initiated FBR & Co. Outperform $6
Feb-24-21 06:54AM  
03:02AM  
Feb-23-21 04:41PM  
04:05PM  
02:30PM  
Feb-22-21 10:29AM  
Feb-18-21 04:05PM  
Feb-16-21 04:05PM  
08:30AM  
Feb-11-21 12:15AM  
Feb-07-21 02:13PM  
Feb-02-21 09:05AM  
Jan-22-21 04:04PM  
Dec-22-20 04:01PM  
Dec-18-20 01:01PM  
Dec-14-20 07:16PM  
Dec-11-20 09:00AM  
Dec-08-20 08:30AM  
Nov-30-20 04:05PM  
Nov-24-20 08:30AM  
Nov-19-20 05:59PM  
Nov-13-20 05:25AM  
Nov-10-20 02:27PM  
09:40AM  
05:58AM  
Nov-09-20 10:00PM  
05:07PM  
04:05PM  
04:01PM  
02:30PM  
Nov-06-20 10:18AM  
Nov-02-20 08:30AM  
Oct-28-20 08:30AM  
Oct-27-20 12:30PM  
Oct-20-20 04:01PM  
Oct-09-20 04:30PM  
Oct-01-20 10:22AM  
08:30AM  
Sep-18-20 04:01PM  
09:00AM  
Sep-16-20 08:30AM  
Sep-11-20 09:59AM  
Sep-09-20 10:40AM  
Sep-04-20 11:41AM  
Sep-03-20 04:01PM  
Sep-01-20 08:30AM  
Aug-19-20 04:01PM  
Aug-05-20 04:01PM  
Jul-29-20 04:01PM  
Jul-17-20 04:01PM  
Jul-13-20 02:33PM  
Jul-12-20 12:02PM  
Jun-18-20 04:01PM  
Jun-15-20 08:30AM  
Jun-08-20 04:30PM  
01:28PM  
Jun-03-20 01:13AM  
Jun-02-20 04:23PM  
Jun-01-20 04:01PM  
09:30AM  
May-28-20 08:30AM  
May-27-20 04:01PM  
May-26-20 08:30AM  
May-22-20 04:30PM  
May-20-20 04:01PM  
May-19-20 04:10PM  
May-13-20 04:01PM  
09:18AM  
May-10-20 08:18AM  
May-08-20 03:01PM  
10:39AM  
May-07-20 04:01PM  
May-06-20 08:30AM  
Apr-30-20 08:30AM  
Apr-24-20 09:00AM  
Apr-19-20 08:27AM  
Apr-14-20 01:47PM  
Apr-10-20 01:09PM  
Apr-07-20 08:05PM  
Apr-01-20 04:01PM  
Mar-30-20 08:30AM  
Mar-18-20 04:01PM  
02:29PM  
Mar-09-20 01:30PM  
10:18AM  
Feb-28-20 05:38AM  
Feb-27-20 01:48PM  
10:40AM  
Feb-26-20 04:01PM  
09:36AM  
Feb-21-20 04:11PM  
Feb-20-20 08:30AM  
Feb-19-20 04:06PM  
Feb-13-20 06:09AM  
Feb-11-20 03:06PM  
Jan-31-20 03:45PM  
Jan-17-20 08:16AM  
Jan-16-20 09:00AM  
Jan-13-20 04:01PM  
Jan-08-20 09:27AM  
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aurentz VincentExecutive VP and CBOFeb 16Option Exercise14.802,52437,35429,524Feb 18 09:00 PM
Aurentz VincentExecutive VP and CBOFeb 16Sale85.002,524214,54027,000Feb 18 09:00 PM
Lisicki RobertEVP, Chief Commercial OfficerFeb 02Option Exercise40.9517,500716,62526,941Feb 04 08:57 PM
Lisicki RobertEVP, Chief Commercial OfficerFeb 02Sale78.8717,5001,380,3089,441Feb 04 08:57 PM
Munshi AmitPresident and CEOJan 19Option Exercise15.5050,000775,00057,750Jan 20 09:05 PM
Dallas Jayson Donald AlexanderDirectorJan 19Sale80.501,327106,8245,308Jan 20 09:06 PM
Munshi AmitPresident and CEOJan 19Sale80.1450,0004,006,7607,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 15Option Exercise15.5050,000775,00057,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 15Sale80.2450,0004,011,9767,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 12Sale75.1214,8771,117,5697,750Jan 14 08:43 PM
Lisicki RobertEVP, Chief Commercial OfficerJan 07Option Exercise0.0012,600012,600Jan 11 09:19 PM
Aurentz VincentExecutive VP and CBOJan 07Option Exercise0.0018,000027,000Jan 11 09:18 PM
Munshi AmitPresident and CEOJan 07Option Exercise0.0023,400031,150Jan 11 09:17 PM
Dallas Jayson Donald AlexanderDirectorDec 11Buy69.3153476,635Dec 15 04:07 PM
Dallas Jayson Donald AlexanderDirectorDec 08Buy66.2553316,630Dec 09 04:03 PM
Munshi AmitPresident and CEODec 08Sale70.006,517456,1987,750Dec 09 04:02 PM
Lisicki RobertEVP, Chief Commercial OfficerDec 01Sale66.063,872255,7860Dec 03 04:02 PM
Lisicki RobertEVP, Chief Commercial OfficerNov 25Option Exercise0.006,30006,300Nov 30 04:02 PM
Cabell ChristopherEVP, Head of R&D, and CMONov 25Option Exercise0.002,50002,500Nov 30 04:01 PM
Munshi AmitPresident and CEONov 25Option Exercise0.0011,700019,450Nov 30 04:00 PM
Aurentz VincentExecutive VP and CBONov 25Option Exercise0.009,00009,000Nov 30 04:00 PM
Munshi AmitPresident and CEOAug 31Option Exercise15.5050,000775,00057,750Aug 31 08:41 PM
Munshi AmitPresident and CEOAug 31Sale70.1050,0003,505,0357,750Aug 31 08:41 PM
Munshi AmitPresident and CEOAug 28Option Exercise15.5050,000775,00057,750Aug 31 08:41 PM
Munshi AmitPresident and CEOAug 28Sale70.0050,0003,500,0007,750Aug 31 08:41 PM
Nova Tina SusanDirectorAug 26Option Exercise18.1317,300313,60033,876Aug 28 05:21 PM
Nova Tina SusanDirectorAug 26Sale67.9417,3001,175,30316,576Aug 28 05:21 PM
Lisicki RobertEVP, Chief Commercial OfficerAug 04Option Exercise40.9530,0001,228,50030,000Aug 06 04:38 PM
Lisicki RobertEVP, Chief Commercial OfficerAug 04Sale63.3430,0001,900,3450Aug 06 04:38 PM
Cabell ChristopherEVP, Head of R&D, and CMOJul 15Option Exercise26.2813,000341,64013,000Jul 17 05:23 PM
Cabell ChristopherEVP, Head of R&D, and CMOJul 15Sale68.0013,000884,0000Jul 17 05:23 PM
Soni Manmeet SinghDirectorJun 17Sale62.7430419,0735,902Jun 18 05:07 PM
Soni Manmeet SinghDirectorJun 15Sale60.121,32779,7796,206Jun 16 08:54 PM
Munshi AmitPresident and CEOJun 03Option Exercise15.3550,000767,67557,750Jun 04 06:34 PM
Munshi AmitPresident and CEOJun 03Sale68.5450,0003,427,2367,750Jun 04 06:34 PM
Aurentz VincentExecutive VP and CBOJun 02Option Exercise19.8025,000495,00025,000Jun 04 06:40 PM
Munshi AmitPresident and CEOJun 02Option Exercise14.6050,000730,00057,750Jun 04 06:34 PM
Munshi AmitPresident and CEOJun 02Sale65.0050,0003,250,0007,750Jun 04 06:34 PM
Aurentz VincentExecutive VP and CBOJun 02Sale65.0025,0001,625,0230Jun 04 06:40 PM
Munshi AmitPresident and CEOMay 22Option Exercise14.6034,800508,08042,550May 22 07:31 PM
Munshi AmitPresident and CEOMay 22Sale58.1234,8002,022,6087,750May 22 07:31 PM
Munshi AmitPresident and CEOMay 21Option Exercise14.6050,000730,00057,750May 22 07:31 PM
Munshi AmitPresident and CEOMay 21Sale55.0050,0002,750,0007,750May 22 07:31 PM